A Non-randomized, Open-label Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Progressing After Prior Therapy With Tyrosine Kinase Inhibitors
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Regorafenib (Primary) ; Sunitinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions
- Acronyms SURE
- 30 Aug 2019 Results (n=14) published in the Clinical Cancer Research.
- 05 Jun 2018 Results (n=14) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 22 Mar 2017 Status changed from recruiting to active, no longer recruiting.